Cell Biochemistry and Biophysics

, Volume 69, Issue 2, pp 229–235 | Cite as

Expression of Sclerostin scFv and the Effect of Sclerostin scFv on Healing of Osteoporotic Femur Fracture in Rats

  • Qi Yao
  • Jie Ni
  • Yu Hou
  • Lixiang Ding
  • Licheng ZhangEmail author
  • Hua JiangEmail author
Original Paper


Osteoporosis is a systemic metabolic disease characterized by low bone mass with deterioration of the bony microstructure which leads to both bone brittleness and increased risk of fracture. Sclerostin is a protein encoded by the SOST gene which is specifically expressed in osteocyte. Monoclonal antibodies of sclerostin can promote bone formation by antagonizing its inhibitory action. However, the effectiveness of monoclonal antibodies to exert such effects are limited by the large molecular mass and high immunogenicity. Here, we report that we purified a high immune affinity, single-chain antibody of SOST: SOST–single-chain Fv (scFv). Real-time polymerase chain reaction amplification of the variable regions of the heavy- and light-chain gene from a secretory anti-SOST antibody was performed. Animal experiments showed that SOST–scFv promoted bone healing in a rat model of osteoporosis.


Osteoporosis Bone healing SOST SOST–scFv scFv Sclerostin Femur fracture VH and VL gene 



The work is supported by the National Natural Science Foundation of China (under Grant 81000796, 81141012) and Beijing Nova Program (under Grant 2011085, 2011120).


  1. 1.
    Rachner, T. D., Khosla, S., & Hofbauer, L. C. (2011). Osteoporosis: Now and the future. Lancet, 377(9773), 1276–1287.PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Lewiecki, E. M. (2011). Sclerostin: A novel target for intervention in the treatment of osteoporosis. Discovery Medicine, 12(65), 263.PubMedGoogle Scholar
  3. 3.
    Ominsky, M. S., et al. (2011). Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. Journal of Bone and Mineral Research, 26, 1012–1021.PubMedCrossRefGoogle Scholar
  4. 4.
    Tian, X., et al. (2011). Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model. Bone, 48(2), 197–201.PubMedCrossRefGoogle Scholar
  5. 5.
    Li, X., et al. (2010). Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. Journal of Bone and Mineral Research, 25(12), 2647–2656.PubMedCrossRefGoogle Scholar
  6. 6.
    Tian, X., et al. (2010). Treatment with a sclerostin antibody increases cancellous bone formation and bone mass regardless of marrow composition in adult female rats. Bone, 47(3), 529–533.PubMedCrossRefGoogle Scholar
  7. 7.
    Agholme, F., et al. (2010). Sclerostin antibody treatment enhances metaphyseal bone healing in rats. Journal of Bone and Mineral Research, 25(11), 2412–2418.PubMedCrossRefGoogle Scholar
  8. 8.
    Ominsky, M. S., et al. (2010). Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. Journal of Bone and Mineral Research, 25(5), 948–959.PubMedCrossRefGoogle Scholar
  9. 9.
    Lewiecki, E. M. (2011). Sclerostin monoclonal antibody therapy with AMG 785: A potential treatment for osteoporosis. Expert Opinion on Biological Therapy, 11(1), 117–127.PubMedCrossRefGoogle Scholar
  10. 10.
    Padhi, D., et al. (2011). Single‐dose, placebo‐controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. Journal of Bone and Mineral Research, 26(1), 19–26.PubMedCrossRefGoogle Scholar
  11. 11.
    Ahmad, Z. A., et al. (2012). scFv antibody: Principles and clinical application. Clinical and Developmental Immunology. Article ID 980250. doi: 10.1155/2012/980250.
  12. 12.
    McCafferty, J., et al. (1990). Phage antibodies: Filamentous phage displaying antibody variable domains. Nature, 348, 552–554.PubMedCrossRefGoogle Scholar
  13. 13.
    Kong, H. Y., Chen, Y. P., Yang, S. Q., et al. (2004). Experimental analysis of osteoporotic detection marker of ovariectomized rats. Chinese Journal of Orthopaedic Trauma, 17(4), 204–206.Google Scholar
  14. 14.
    Lane, N. E., & Silverman, S. L. (2010). Anabolic therapies. Current Osteoporosis Reports, 8(1), 23–27.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Sibai, T., et al. (2011). Anabolic agents and bone quality. Clinical Orthopaedics and Related Research, 469(8), 2215–2224.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Papapoulos, S. E. (2011). Targeting sclerostin as potential treatment of osteoporosis. Annals of the Rheumatic Diseases, 70(Suppl 1), i119–i122.PubMedCrossRefGoogle Scholar
  17. 17.
    Moester, M., et al. (2010). Sclerostin: Current knowledge and future perspectives. Calcified Tissue International, 87(2), 99–107.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Geng, S., et al. (2006). Binding activity difference of anti-CD20 scFv-Fc fusion protein derived from variable domain exchange. Cellular and Molecular Immunology, 3(6), 439–443.PubMedGoogle Scholar
  19. 19.
    Luo, D., et al. (1995). VI–linker–VH orientation-dependent expression of single chain Fv containing an engineered disulfide-stabilized bond in the framework regions. Journal of Biochemistry, 118(4), 825–831.PubMedGoogle Scholar
  20. 20.
    Robert, B., et al. (1999). Tumor targeting with newly designed biparatopic antibodies directed against two different epitopes of the carcinoembryonic antigen (CEA). International Journal of Cancer, 81(2), 285–291.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of OrthopaedicsBeijing Shijitan Hospital Affiliated to Capital Medical UniversityBeijingChina
  2. 2.Department of OrthopaedicsChinese PLA General HospitalBeijingChina
  3. 3.Department of StomatologyChinese PLA General HospitalBeijingChina

Personalised recommendations